CV CapsoVision, Inc
Q3 2025 10-Q
Filed: Nov 13, 2025Period ending Sep 30, 2025
Health Care
Electromedical & Electrotherapeutic ApparatusSEC EDGAR CapsoVision, Inc (CV) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New risk: FDA Breakthrough Device Designation submitted for pancreatic cancer capsule endoscopy solution Nov 6, 2025, uncertain eligibility and authorization timing
- • Updated regulatory risk: Potential delays in FDA 510(k) clearance for CapsoCam Colon second-generation due to FDA staff reductions and government shutdowns still unresolved
Quarterly Financial SummaryXBRL
Revenue
$4M
Net Income
-$8M
Gross Margin
54.1%
Operating Margin
-226.7%
Net Margin
-223.9%
ROE
-38.7%
Total Assets
$26M
Source: XBRL data from CapsoVision, Inc Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on CapsoVision, Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.